Completed
PHASE2
INTERVENTIONAL
NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change from Baseline in Glomerular Filtration Rate (mGFR)
TimeFrame:
Baseline, Week 24
Description:
The GFR in milliliter/minute per1.73 square meter (mL/min/1.73 m²) using iohexol clearance (mGFR-measured glomerular filtration rate)
Trial Information
NCT ID
NCT05936151
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025